We collaborate with you to select the optimal conjugation strategy based on the final application. For ADCs, we focus on Drug-to-Antibody Ratio (DAR), stability, and potency. For fluorescent probes, we prioritize brightness, photos tability, and minimal functional interference.

Site-Specific Conjugation (e.g., Cysteine-engineered, FC-region): We employ proprietary methods for homogeneous DAR (typically DAR 2, 4, or 8) with minimal aggregation, overcoming the heterogeneity of traditional stochastic methods.

Controlled Lysine Conjugation: Advanced process control ensures a narrow DAR distribution (e.g., DAR 4 ± 0.5), enhancing batch-to-batch reproducibility.

Wide Payload Compatibility: We have proven expertise with diverse payloads, including MMAE, DM1, Duocarmycins, and topoisomerase inhibitors.

Controlled Stoichiometry: We precisely control the degree of labeling to maximize signal-to-noise ratio while preserving antigen-binding capability.

Broad Dye Compatibility: Services include labeling with FITC, PE/Cy5, Alexa Fluor® dyes (488, 647, 700), all performed with light-protected processes to prevent dye degradation.

We utilize hydrophobic interaction chromatography (HIC) and size-exclusion chromatography (SEC) to efficiently remove free payloads/dyes, aggregates, and under-conjugated species.

For ADCs: We provide full characterization including DAR calculation (by HIC-HPLC or MS), aggregation level (SEC-HPLC), endotoxin testing.

For Fluorescent Conjugates: We report exact functionality (ELISA/flow cytometry), and purity (SEC-HPLC).

FedEx, DHL, and UPS for international priority shipping.

We formulate your antibody in a buffer optimized for long-term stability (-80°C) and immediate use in common applications.

You receive a comprehensive data package, including the CoA, QC graphs, and recommended storage/usage protocols.